Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ProbiusDx is a private healthcare and life-science tools company developing a bioanalytical platform based on Quantum Electrochemical Spectroscopy (QES). The company positions QES as a label-free, reagent-free electrochemical sensing and machine-learning platform that converts small biological samples into high-dimensional digital signatures, or "digital twins," for downstream analysis. Its MiniQES system and cloud software are aimed at biomarker discovery, analyte quantitation, preclinical research, bioproduction quality control, and other bioanalysis workflows rather than drug development. ProbiusDx appears to commercialize instrumentation, consumables, and analytics services for pharma, biotech, and research users, while also running a collaborative QESLab program to generate application data and external validation. The company is focused on enabling broad-spectrum biological measurement from minimal sample volumes with simplified workflows.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ProbiusDx.